
Galapagos NV – NASDAQ:GLPG
Galapagos NV stock price today
Galapagos NV stock price monthly change
Galapagos NV stock price quarterly change
Galapagos NV stock price yearly change
Galapagos NV key metrics
Market Cap | 1.75B |
Enterprise value | 1.86B |
P/E | -10.47 |
EV/Sales | 3.22 |
EV/EBITDA | 27.85 |
Price/Sales | 3.70 |
Price/Book | 0.79 |
PEG ratio | -0.15 |
EPS | 0.95 |
Revenue | 123.28M |
EBITDA | -51.61M |
Income | 278.71M |
Revenue Q/Q | -65.09% |
Revenue Y/Y | -77.49% |
Profit margin | 0.96% |
Oper. margin | -82.54% |
Gross margin | 98.46% |
EBIT margin | -82.54% |
EBITDA margin | -41.86% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGalapagos NV stock price history
Galapagos NV stock forecast
Galapagos NV financial statements
Jun 2023 | 149.95M | 5.10M | 3.4% |
---|---|---|---|
Sep 2023 | 120.02M | 25.83M | 21.52% |
Dec 2023 | -209.12M | 157.55M | -75.34% |
Mar 2024 | 62.43M | 90.22M | 144.51% |
Mar 2024 | 62.43M | 90.22M | 144.51% |
---|---|---|---|
Sep 2025 | 60.13M | 5.18M | 8.63% |
Dec 2025 | 69.93M | -13.04M | -18.65% |
Dec 2025 | 60.13M | 5.18M | 8.63% |
Analysts Price target
Financials & Ratios estimates
2023-05-04 | -0.87 | 0.43 |
---|---|---|
2023-08-03 | 1.08 | -0.31 |
Jun 2023 | 4522340000 | 1.93B | 42.86% |
---|---|---|---|
Sep 2023 | 4451336000 | 1.82B | 41.11% |
Dec 2023 | 4357396000 | 1.56B | 35.84% |
Mar 2024 | 4361379000 | 1.46B | 33.62% |
Jun 2023 | -125.41M | 100.90M | -1.55M |
---|---|---|---|
Sep 2023 | -118.81M | 182.53M | -2.06M |
Dec 2023 | -66.86M | 76.40M | -1.19M |
Mar 2024 | -117.78M | 25.01M | -1.16M |
Galapagos NV alternative data
Aug 2023 | 1,338 |
---|---|
Sep 2023 | 1,233 |
Oct 2023 | 1,233 |
Nov 2023 | 1,233 |
Dec 2023 | 1,338 |
Jan 2024 | 1,338 |
Feb 2024 | 1,338 |
Mar 2024 | 1,338 |
Apr 2024 | 1,338 |
May 2024 | 1,123 |
Jun 2024 | 1,123 |
Jul 2024 | 1,123 |
Galapagos NV other data
Patent |
---|
Application Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use Filling date: 27 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 25 May 2020 Issue date: 28 Jul 2022 |
Application NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. Filling date: 12 Nov 2021 Issue date: 21 Jul 2022 |
Application Filling date: 24 Mar 2020 Issue date: 14 Jul 2022 |
Application Filling date: 21 Apr 2020 Issue date: 30 Jun 2022 |
Application Filling date: 24 Mar 2020 Issue date: 23 Jun 2022 |
Application Filling date: 3 Sep 2021 Issue date: 2 Jun 2022 |
Grant Utility: Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use Filling date: 2 Jun 2020 Issue date: 31 May 2022 |
Grant Filling date: 26 Nov 2018 Issue date: 24 May 2022 |
Application Filling date: 17 Feb 2020 Issue date: 12 May 2022 |
Quarter | Transcript |
---|---|
Q1 2024 3 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 23 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 5 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 4 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Onno Van De Stolpe (1959) Co-Founder, Chairman of the Management Board, MD & Chief Executive Officer | $1,000,000 |
Mr. Bart Filius M.B.A., MBA (1970) Pres, Chief Operating Officer & Member of Management Board | $642,120 |
Dr. Walid Abi-Saab (1965) Chief Medical Officer & Member of Management Board | $613,110 |
Dr. Andre Hoekema (1957) Chief Bus. Officer & Member of Management Board | $578,000 |
Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating
Galapagos: Deeply Into Negative EV Territory, Exciting BD Optionality, Buy
MorphoSys: Negative Enterprise Value Biotech, But Lack Of Near-Term Catalyst
Galapagos: Slow Transformation, But Led By An Expert
Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product
Takeda Pharmaceutical Vs. Gilead Sciences: Who Is The Dividend King?
Galapagos: Can The Company Turn Around?
Galapagos: A History Of Disruptive Failures
Galapagos: The Investment Thesis Is More Appealing Than Ever
-
What's the price of Galapagos NV stock today?
One share of Galapagos NV stock can currently be purchased for approximately $32.1.
-
When is Galapagos NV's next earnings date?
Unfortunately, Galapagos NV's (GLPG) next earnings date is currently unknown.
-
Does Galapagos NV pay dividends?
No, Galapagos NV does not pay dividends.
-
How much money does Galapagos NV make?
Galapagos NV has a market capitalization of 1.75B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 52.56% to 239.72M US dollars. Galapagos NV earned 211.7M US dollars in net income (profit) last year or -$0.31 on an earnings per share basis.
-
What is Galapagos NV's stock symbol?
Galapagos NV is traded on the NASDAQ under the ticker symbol "GLPG".
-
What is Galapagos NV's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Galapagos NV?
Shares of Galapagos NV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Galapagos NV's key executives?
Galapagos NV's management team includes the following people:
- Mr. Onno Van De Stolpe Co-Founder, Chairman of the Management Board, MD & Chief Executive Officer(age: 66, pay: $1,000,000)
- Mr. Bart Filius M.B.A., MBA Pres, Chief Operating Officer & Member of Management Board(age: 55, pay: $642,120)
- Dr. Walid Abi-Saab Chief Medical Officer & Member of Management Board(age: 60, pay: $613,110)
- Dr. Andre Hoekema Chief Bus. Officer & Member of Management Board(age: 68, pay: $578,000)
-
Is Galapagos NV founder-led company?
Yes, Galapagos NV is a company led by its founder Mr. Onno Van De Stolpe.
-
How many employees does Galapagos NV have?
As Jul 2024, Galapagos NV employs 1,123 workers, which is 16% less then previous quarter.
-
When Galapagos NV went public?
Galapagos NV is publicly traded company for more then 13 years since IPO on 27 Feb 2012.
-
What is Galapagos NV's official website?
The official website for Galapagos NV is glpg.com.
-
How can i contact Galapagos NV?
Galapagos NV can be reached via phone at +32 15 34 29 00.
Galapagos NV company profile:

Galapagos NV
glpg.comNASDAQ
1,123
Biotechnology
Healthcare
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Mechelen, 2800
CIK: 0001421876
ISIN: US36315X1019
CUSIP: 36315X101